Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Alzheimer's Disease by Phase

  • There are currently 256 ongoing clinical trials involving Alzheimer's Disease

  • Of the 256 trials,103 trials are in Phase II

  • Furthermore, 60 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Alzheimer's Disease by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Alzheimer’s Disease, a Central Nervous System disorder. North America boasts the highest number of ongoing clinical trials involving Alzheimer’s Disease. Asia-Pacific and Europe are among some of the other prominent regions involved in Alzheimer’s Disease-related drug trials.

Eli Lilly and Co: The leading ongoing Alzheimer’s Disease-related clinical trials sponsor

Eli Lilly and Co, the United States of America-based pharmaceutical company, is the top sponsor for Alzheimer’s Disease-related ongoing clinical trials.

F. Hoffmann-La Roche LtdEisai Co Ltd, Cognition Therapeutics Inc, Cassava Sciences Inc, and Johns Hopkins University are a few other notable sponsors involving Alzheimer’s Disease.

 A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Alzheimer’s Disease

Donepezil hydrochloride (Aricep; Aricept; Donepezil; Eranz; Neuristor), and Memantine hydrochloride(Abixa; Axura; Ebix; Ebixa; Memantine Akatinol; Memantine Hydrochloride Daiich; Memantine Hydrochloride; Memantine; Memary; Namenda)are among the key marketed drugs involving Alzheimer’s Disease.

Donepezil hydrochloride (Aricep; Aricept; Donepezil; Eranz; Neuristor), an Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) Inhibitor, is indicated for the treatment of dementia of the Alzheimer’s type and Lewy body dementia. The drug is marketed in the United States of America, China, Japan, and the United Kingdom by Eisai Co Ltd. Donepezil hydrochloride was first approved in 1996 and formulated as film-coated tablets and tablets for the oral route of administration.

Memantine hydrochloride (Abixa; Axura; Ebix; Ebixa; Memantine Akatinol; Memantine Hydrochloride Daiich; Memantine Hydrochloride; Memantine; Memary; Namenda), a Glutamate Ionotropic Receptor NMDA Type Subunit (NMDAR or GRIN) Antagonist, is used to treat Alzheimer’s Disease, Dementia Associated With Alzheimer's Disease, and Vascular Dementias. The drug is marketed globally including the United States, Australia, France, Germany, and Japan by Merz Pharma GmbH & Co KgaA. Memantine hydrochloride was first approved in 2002 and is sold in the form of film-coated tablets, tablets, powder for solution and solution, and drops for oral administration.



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer